These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9180103)

  • 1. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group.
    Kawai C; Yui Y; Hosoda S; Nobuyoshi M; Suzuki S; Sato H; Takatsu F; Motomiya T; Kanmatsuse K; Kodama K; Yabe Y; Minamino T; Kimata S; Nakashima M
    J Am Coll Cardiol; 1997 Jun; 29(7):1447-53. PubMed ID: 9180103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel modified tissue-type plasminogen activator (t-PA), E6010, reduces reperfusion arrhythmias induced after coronary thrombolysis--comparison of native t-PA and urokinase.
    Saito M; Suzuki S; Yui Y; Kawai C
    Jpn Circ J; 1995 Aug; 59(8):556-64. PubMed ID: 7474300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
    Hackett D; Andreotti F; Haider AW; Brunelli C; Shahi M; Fussell A; Buller N; Foale R; Lipkin D; Caponnetto S
    Am J Cardiol; 1992 Jun; 69(17):1393-8. PubMed ID: 1590225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
    Saito M; Suzuki S; Yui Y; Kawai C
    Jpn J Pharmacol; 1994 Sep; 66(1):17-23. PubMed ID: 7532243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig.
    Adachi H; Nagaoka N; Nomoto K; Yuzuriha T; Shoji T
    Jpn J Pharmacol; 1992 Mar; 58(3):309-19. PubMed ID: 1513078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel modified t-PA, E-6010, induces faster recovery of ventricular function after coronary thrombolysis than native t-PA in a canine thrombosis model.
    Suzuki S; Saito M; Yui Y; Kawai C
    Jpn Circ J; 1995 Apr; 59(4):205-12. PubMed ID: 7658613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
    J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
    Brener SJ; Zeymer U; Adgey AA; Vrobel TR; Ellis SG; Neuhaus KL; Juran N; Ivanc TB; Ohman EM; Strony J; Kitt M; Topol EJ
    J Am Coll Cardiol; 2002 Feb; 39(3):377-86. PubMed ID: 11823073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
    Purvis JA; McNeill AJ; Siddiqui RA; Roberts MJ; McClements BM; McEneaney D; Campbell NP; Khan MM; Webb SW; Wilson CM
    J Am Coll Cardiol; 1994 Jan; 23(1):6-10. PubMed ID: 8277097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
    Suzuki N; Suzuki S; Nagaoka N; Mizuo H; Yuzuriha T; Yoshitake S; Kanmatuse K
    Jpn J Pharmacol; 1994 Jul; 65(3):257-63. PubMed ID: 7799526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].
    Sarullo FM; Schicchi R; Schirò M; Americo L; Bonnì G; Faraone N; Di Pasquale P; Castello A; Mauri F
    Ital Heart J Suppl; 2000 Jan; 1(1):81-7. PubMed ID: 10832123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.
    Nagao K; Satou K; Watanabe I; Arima K; Yamashita M; Ooiwa K; Kanmatsuse K
    Jpn Circ J; 1998 Feb; 62(2):111-4. PubMed ID: 9559429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
    Van de Werf F; Lijnen HR; Collen D
    Coron Artery Dis; 1993 Oct; 4(10):929-33. PubMed ID: 8269200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.